Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
FOSTER CITY, Calif. - Gilead Sciences (NASDAQ:GILD) reported fourth quarter results that topped analyst expectations and provided an optimistic forecast for 2025, sending shares up 3.5% in after-hours trading on Tuesday.
The biopharmaceutical company posted adjusted earnings per share of $1.90 on revenue of $7.6 billion for Q4 2024. This exceeded Wall Street estimates of $1.71 EPS on $7.16 billion in revenue.
Total (EPA:TTEF) product sales increased 7% YoY to $7.5 billion in Q4, driven by 16% growth in HIV product sales to $5.5 billion. Biktarvy sales jumped 21% to $3.8 billion.
"Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% YoY for the fourth quarter," said CEO Daniel O’Day.
For full-year 2025, Gilead forecasts revenue between $28.2-$28.6 billion and adjusted EPS of $7.70-$8.10. Both ranges came in above the consensus analyst estimates.
The company highlighted its strong commercial foundation and potential launch of lenacapavir for HIV prevention in summer 2025 as key growth drivers going forward.
Gilead ended 2024 with $10 billion in cash and investments. The board declared a quarterly dividend of $0.79 per share.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.